Skip to main content
UniHealth

Doctor search

Yashaar Chaichian, MD

Rheumatology · Stanford

NPI 1174788103

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
17
3 carriers
Offices
3

Offices

3 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chaichian’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A136358 · Current

Licensed to practise in California · since 2015 · expires 2027-04-30 · University of Iowa Roy J. and Lucille A. Carver College of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$83,930

Medicare paid this office $83,930 for 259 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)145$38,513$156
Long return visit (40+ min)96$18,891$117
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes19$4,448$106
New patient visit (60+ min)24$4,342$181
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's123$3,287$15
See all 10 services
Every Original Medicare service billed
Long return visit (40+ min)145$38,513$156
Long return visit (40+ min)96$18,891$117
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes19$4,448$106
New patient visit (60+ min)24$4,342$181
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's123$3,287$15
New patient visit (60+ min)20$3,242$162
Initial hospital care with moderate level of medical decision making at least 75 minutes19$2,938$155
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or45$2,304$30
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's87$2,080$15
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or27$1,128$28

Who their Medicare patients are

259 Original Medicare patients in 2024. Average age 69 · Under 65 22% · 85 and older 6% · Women 72% · Also on Medicaid 33% · Health risk score 1.97. Sicker patients than 9 in 10 peers; the typical rheumatology clinician is at 1.38.

Conditions among them: High blood pressure 65% · Chronic kidney disease 29% · Diabetes 27% · Coronary heart disease 25% · Depression 25% · Heart failure 19% · Atrial fibrillation 17% · Cancer 16% · COPD 15% · Stroke 8% · Dementia 6%.

The office billed $387,022, Medicare allowed $113,136 and paid $83,930; for 1,028 services of 11 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20242591,028691.97$387,022$83,930
2023224573681.68$285,718$56,854
2022276741691.69$371,844$68,939
2021268794671.76$425,274$73,791
2020207518671.86$243,969$43,176
2019188385681.97$141,511$34,351
2018225424671.90$128,856$37,226
2017235457652.09$135,497$41,983
2016176331651.72$90,274$27,890
2015111145641.77$37,947$11,177

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 6 services

Original Medicare services billed in 2023
Long return visit (40+ min)156$37,423$124
New patient visit (60+ min)37$5,899$159
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or61$3,795$29
Long return visit (40+ min)14$2,816$117
Initial hospital care with moderate level of medical decision making at least 75 minutes13$2,079$160
Return visit (30+ min)23$1,807$79

2022: 10 services

Original Medicare services billed in 2022
Long return visit (40+ min)143$31,953$125
New patient visit (60+ min)55$9,049$165
Long return visit (40+ min)46$6,600$125
Return visit (30+ min)50$4,599$82
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or74$4,129$29
Initial hospital care with moderate level of medical decision making at least 75 minutes18$3,255$181
New patient visit (60+ min)14$2,590$185
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes13$2,251$94
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or22$1,125$27
Telehealth originating site facility fee45$943$20

2021: 12 services

Original Medicare services billed in 2021
Long return visit (40+ min)105$20,391$126
Long return visit (40+ min)59$11,508$162
New patient visit (60+ min)61$10,373$170
Return visit (30+ min)56$5,244$82
New patient visit (60+ min)25$5,178$207
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or59$3,777$30
Initial hospital care with moderate level of medical decision making at least 75 minutes17$3,146$185
Telephone medical discussion with physician, 21-30 minutes21$2,756$79
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes14$2,609$93
Return visit (30+ min)23$2,567$107
Telehealth originating site facility fee82$2,211$21
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or23$1,277$31

2020: 8 services

Original Medicare services billed in 2020
Return visit (30+ min)84$8,525$65
Long return visit (40+ min)63$8,044$104
New patient visit (60+ min)43$5,941$138
Return visit (30+ min)49$5,807$91
New patient visit (60+ min)20$3,526$176
Telephone medical discussion with physician, 21-30 minutes31$2,951$72
Long return visit (40+ min)18$2,944$140
Telehealth originating site facility fee68$1,701$21

2019: 6 services

Original Medicare services billed in 2019
Return visit (30+ min)87$11,552$67
Return visit (30+ min)34$6,286$92
New patient visit (60+ min)26$4,756$183
New patient visit (60+ min)27$3,595$133
Initial hospital care with moderate level of medical decision making at least 75 minutes12$2,202$184
Long return visit (40+ min)14$1,592$94

2018: 8 services

Original Medicare services billed in 2018
Return visit (30+ min)96$8,799$64
New patient visit (60+ min)44$6,155$140
New patient visit (60+ min)31$5,892$190
Long return visit (40+ min)42$4,569$91
Return visit (30+ min)30$3,761$87
Initial hospital care with moderate level of medical decision making at least 75 minutes11$2,001$182
Short return visit (20+ min)34$1,682$40
Short return visit (20+ min)12$947$68

2017: 9 services

Original Medicare services billed in 2017
Return visit (30+ min)101$9,279$65
Long return visit (40+ min)60$7,694$95
New patient visit (60+ min)51$7,377$145
New patient visit (60+ min)25$4,127$165
Return visit (30+ min)21$3,392$89
Long return visit (40+ min)13$2,017$112
New patient visit (45+ min)17$1,936$114
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes13$1,749$65
Short return visit (20+ min)12$502$42

2016: 7 services

Original Medicare services billed in 2016
Return visit (30+ min)85$8,431$62
Long return visit (40+ min)42$5,561$91
New patient visit (60+ min)27$3,803$141
New patient visit (60+ min)18$2,645$147
Return visit (30+ min)13$1,331$70
New patient visit (45+ min)13$1,269$98
Aspiration and/or injection of fluid from large joint12$636$42

2015: 3 services

Original Medicare services billed in 2015
Return visit (30+ min)54$4,416$68
Long return visit (40+ min)31$2,874$93
New patient visit (45+ min)18$2,084$116

Medicaid work

$15,327 in 2024

Medicaid paid $15,327 for 193 billed services this clinician did in 2024, up to 25 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)193$15,327
Medicaid work by year
2024193125$15,327
2023227126$12,779
2022157121$9,470
2021151121$9,579
202069217$3,445
2019154123$6,104
201885117$3,465
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Long return visit (40+ min)227$12,779

2022

Largest Medicaid services in 2022
Long return visit (40+ min)157$9,470

2021

Largest Medicaid services in 2021
Long return visit (40+ min)151$9,579

2020

Largest Medicaid services in 2020
Return visit (30+ min)56$2,617
Long return visit (40+ min)13$828

2019

Largest Medicaid services in 2019
Return visit (30+ min)154$6,104

2018

Largest Medicaid services in 2018
Return visit (30+ min)85$3,465

Drugs they prescribed that Part D paid

$1,457,487

Pharmacies billed $1,457,487 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 868) in 2024. At or below the middle of the specialty; the typical rheumatology clinician is at 3%.

664 generic and fewer than 11 brand-name prescriptions · $1,457,487 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Enbrel SureclickNone53$405,190$7,645
Actemra ActpenNone20$150,938$7,547
BenlystaNone19$139,371$7,335
PanzygaImmune globulin11$123,681$11,244
Orencia ClickjectNone15$94,793$6,320
See all 16 drugs
Every Part D drug this clinician prescribed
Enbrel SureclickNone53$405,190$7,645
Actemra ActpenNone20$150,938$7,547
BenlystaNone19$139,371$7,335
PanzygaImmune globulin11$123,681$11,244
Orencia ClickjectNone15$94,793$6,320
CevimelineNone26$6,037$232
Hydroxychloroquine SulfateNone121$5,387$45
Mycophenolate MofetilNone25$4,043$162
LeflunomideNone55$3,661$67
MethotrexateNone124$3,310$27
ColchicineNone27$2,466$91
AzathioprineNone32$1,727$54
PrednisoneNone126$1,331$11
AllopurinolNone35$342$10
LidocaineNone11$198$18
Folic AcidNone25$128$5

Year by year

Part D prescribing by year
20248681710% (0)None$1,457,487
20238511530% (0)None$1,478,319
20227351350% (0)19%$822,545
20217111320% (0)21%$732,715
20206881090% (0)None$746,280
2019649105NoneNone$632,740
2018717135None18%$495,457
2017614132None16%$208,903
2016562117NoneNone$151,202
2015298102NoneNone$59,588
2014443875% (21)None$66,839
2013425763% (14)None$83,510

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 14 drugs

Part D drugs prescribed in 2023
Enbrel SureclickNone46$334,292$7,267
PanzygaImmune globulin27$278,460$10,313
Humira(Cf)None20$204,059$10,203
EnbrelNone13$137,132$10,549
BenlystaNone16$121,858$7,616
Hydroxychloroquine SulfateNone135$9,828$73
CevimelineNone19$5,916$311
LeflunomideNone73$5,814$80
Mycophenolate MofetilNone39$5,644$145
MethotrexateNone119$5,524$46
ColchicineNone24$3,367$140
PrednisoneNone133$2,114$16
AzathioprineNone17$2,064$121
AllopurinolNone34$564$17

2022: 12 drugs

Part D drugs prescribed in 2022
Enbrel Sureclick35$239,006$6,829
Benlysta20$87,321$4,366
Enbrel12$75,146$6,262
Vemlidy13$18,224$1,402
Hydroxychloroquine Sulfate130$9,826$76
Leflunomide52$5,611$108
Methotrexate135$4,981$37
Mycophenolate Mofetil31$3,062$99
Azathioprine20$2,262$113
Prednisone134$2,110$16
Colchicine12$1,937$161
Allopurinol14$222$16

2021: 13 drugs

Part D drugs prescribed in 2021
Enbrel Sureclick34$208,050$6,119
Benlysta33$159,449$4,832
Humira(Cf)16$123,986$7,749
Enbrel12$69,534$5,794
Hydroxychloroquine Sulfate124$8,103$65
Methotrexate128$6,410$50
Leflunomide43$5,519$128
Mycophenolate Mofetil36$4,109$114
Colchicine24$3,790$158
Prednisone116$1,985$17
Azathioprine14$1,423$102
Sulfasalazine15$354$24
Alendronate14$145$10

2020: 17 drugs

Part D drugs prescribed in 2020
Enbrel Sureclick29$161,586$5,572
Orencia13$82,899$6,377
Humira(Cf)14$80,400$5,743
Benlysta18$77,437$4,302
Xeljanz14$48,565$3,469
Hydroxychloroquine Sulfate107$10,541$99
Mycophenolate Mofetil48$5,802$121
Leflunomide29$5,335$184
Methotrexate101$4,840$48
Colchicine15$4,601$307
Febuxostat11$2,455$223
Azathioprine22$1,614$73
Prednisone112$1,159$10
Sulfasalazine18$783$43
Fluoxetine12$190$16
Omeprazole11$104$9
Alendronate15$84$6

2019: 15 drugs

Part D drugs prescribed in 2019
Enbrel Sureclick15$77,222$5,148
Enbrel17$71,488$4,205
Benlysta11$69,674$6,334
Humira(Cf)12$62,741$5,228
Xeljanz11$49,416$4,492
Hydroxychloroquine Sulfate102$9,530$93
Leflunomide24$7,706$321
Mycophenolate Mofetil36$4,637$129
Methotrexate91$4,199$46
Prednisone124$1,494$12
Azathioprine21$833$40
Sulfasalazine19$546$29
Diclofenac15$446$30
Allopurinol12$212$18
Sulfamethoxazole-Trimethoprim12$67$6

2018: 15 drugs

Part D drugs prescribed in 2018
Xeljanz Xr13$65,844$5,065
Humira12$60,417$5,035
Enbrel16$58,135$3,633
Xeljanz11$45,661$4,151
Hydroxychloroquine Sulfate127$15,929$125
Leflunomide22$9,163$417
Methotrexate111$6,247$56
Mycophenolate Mofetil34$3,329$98
Prednisone163$1,983$12
Azathioprine11$760$69
Allopurinol32$601$19
Voltaren11$577$52
Diclofenac15$507$34
Sulfasalazine11$412$37
Meloxicam12$52$4

2017: 10 drugs

Part D drugs prescribed in 2017
Hydroxychloroquine Sulfate106$21,806$206
Methotrexate120$8,520$71
Leflunomide16$8,400$525
Mycophenolate Mofetil24$2,466$103
Prednisone141$1,824$13
Colchicine15$1,563$104
Diclofenac23$1,054$46
Voltaren15$787$52
Allopurinol37$736$20
Sulfamethoxazole-Trimethoprim13$50$4

2016: 10 drugs

Part D drugs prescribed in 2016
Enbrel11$30,360$2,760
Hydroxychloroquine Sulfate68$12,657$186
Methotrexate93$8,253$89
Leflunomide13$5,149$396
Mycophenolate Mofetil39$4,437$114
Prednisone136$2,287$17
Voltaren25$1,227$49
Azathioprine20$956$48
Sulfasalazine15$559$37
Sulfamethoxazole-Trimethoprim24$92$4

2015: 4 drugs

Part D drugs prescribed in 2015
Hydroxychloroquine Sulfate64$11,551$180
Methotrexate38$2,975$78
Prednisone53$979$18
Voltaren11$519$47

2014: 9 drugs

Part D drugs prescribed in 2014
Methotrexate42$3,275$78
Mycophenolate Mofetil14$2,311$165
Hydroxychloroquine Sulfate80$2,079$26
Prednisone50$1,124$22
Azathioprine11$525$48
Omeprazole14$306$22
Alendronate16$183$11
Allopurinol14$148$11
Tramadol11$60$5

2013: 14 drugs

Part D drugs prescribed in 2013
Humira12$38,488$3,207
Enbrel11$24,930$2,266
Calcium Acetate11$2,364$215
Methotrexate29$1,972$68
Hydroxychloroquine Sulfate45$1,147$25
Prednisone58$852$15
Montelukast11$298$27
Omeprazole16$209$13
Clonidine12$157$13
Leucovorin11$150$14
Lisinopril17$94$6
Allopurinol12$71$6
Metoprolol12$62$5
Amlodipine Besylate12$56$5

Money from drug and device companies

$1,125 in 2024

Industry payments by year
202412None$1,125
202222$2,880$2,985
202011$4,600$4,600
201929None$1,332

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
GlaxoSmithKlineBenlysta$1,125
2 payments
  • Meals for Benlysta · 2024-04-10 · $125
  • Travel for Benlysta · 2024-04-10 · $1,000
See all 2 published payments
Every published payment
GlaxoSmithKlineMeals · 2024-04-10Benlysta$125
GlaxoSmithKlineTravel · 2024-04-10Benlysta$1,000
See earlier years (2022, 2020, 2019)

2022: $2,985

Payments by company in 2022
Boehringer Ingelheim PharmaceuticalsOfev$2,880
1 payment
  • Consulting for Ofev · 2022-04-05 · $2,880
Aurinia Pharma U.S.Lupkynis$105
1 payment
  • Meals for Lupkynis · 2022-11-13 · $105

2020: $4,600

Payments by company in 2020
GlaxoSmithKlineNucala$4,600
1 payment
  • Consulting for Nucala · 2020-04-18 · $4,600

2019: $1,332

Payments by company in 2019
GlaxoSmithKlineNucala$1,219
8 payments
  • Meals for Nucala · 2019-12-07 · $44
  • Meals for Nucala · 2019-12-07 · $48
  • Meals for Nucala · 2019-12-07 · $54
  • Travel for Nucala · 2019-12-06 · $151
  • Travel for Nucala · 2019-12-03 · $707
  • Meals for Benlysta · 2019-04-07 · $92
  • Travel for Benlysta · 2019-01-04 · $36
  • Meals for Benlysta · 2019-01-04 · $86
PfizerNone$113
1 payment
  • Travel · 2019-08-01 · $113

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Eli Lilly and Company · A Randomized, Double Blind, Placebo Controlled, Phase 2 Study of Ly3471851 (Nktr 358) in Adults With Systemic Lupus Erythematosus · 2022Their institution$40,421
Eli Lilly and Company · A Randomized Double Blind Placebo Controlled Phase 2 Study of Ly3471851 (Nktr 358) in Adults With Systemic Lupus Erythematosus · 2023Their institution$18,936
Gilead Sciences, Inc. · A Phase 2, Randomized, Parallel Group, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and Gs-9876 in Subjects With Lupus Membranous Nephropathy · 2019Their institution$15,514
Amgen Inc. · Phase 2b - Sle Dose-Finding · 2021Their institution$10,544
Amgen Inc. · Phase 2b Sle Dose-Finding · 2020Their institution$8,128
Amgen Inc. · P2b Sle Dose-Finding · 2022Their institution$3,424
Eli Lilly and Company · A Randomized, Double Blind, Placebo Controlled, Phase 2 Study of Ly3471851 (Nktr 358) in Adults With Systemic Lupus Erythematosus · 2021Their institution$2,227
Eli Lilly and Company · A Randomized, Double Blind, Placebo Controlled, Phase 2 Study of Ly3471851 (Nktr 358) in Adults With Systemic Lupus Erythematosus · 2020Their institution$1,164
Eli Lilly and Company · A Randomized, Double Blind, Placebo Controlled, Phase 2 Study of Ly3471851 (Nktr 358) in Adults With Systemic Lupus Erythematosus · 2024Their institution$750
Amgen Inc. · P2b Sle Dose-Finding · 2023Their institution$346

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1174788103
Licence
CA A136358California A136358: Current · expires 2027-04-30
Trained
University of Iowa, Rj & L Carver College of Medicine, 2008
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207RR0500X (207RR0500X); Internal medicine (207R00000X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2008-07-18
NPI last updated
2024-04-16
NPI record certified
2024-04-16

This is when the NPI record was last certified, not a medical board exam.